---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-006981"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:26:44.371536+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma FY2025 net loss $223.1M; cash $188.9M; KRESLADI PDUFA March 28, 2026

## Summary
- Net loss $223.1M ($2.01/shr) vs $258.7M ($2.73/shr) in FY2024; R&D spend down 17% to $142.0M.
- Cash, cash equivalents & investments $188.9M; runway into Q2 2027; restructuring charges $3.2M.
- Pivotal Phase 2 trial of RP-A501 (Danon disease) to resume 1H 2026 after FDA lifted clinical hold.
- KRESLADI BLA resubmission accepted; PDUFA target action date March 28, 2026; eligible for PRV.
- First patient dosing in Phase 1 RP-A701 (BAG3-DCM) expected mid-2026; Phase 1 trial startup ongoing.

## SEC filing metadata
- accession: 0001140361-26-006981
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/0001140361-26-006981-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036126006981/ef20066645_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-006981
- JSON: https://secwatch.observer/filing/0001140361-26-006981.json
- Plain text: https://secwatch.observer/filing/0001140361-26-006981.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.